In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

A new study published in The Journal of Bone and Joint Surgery showed that when glucagon-like peptide-1 receptor agonist (GLP ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

Patients with obesity and comorbid cardiovascular disease were more likely to ration prescription drugs than those without obesity.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Scientists have found a way to help the body make more of an Ozempic-like fullness hormone to cut cravings and improve health.